---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-015887"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:26:48.891796+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics Q1 FY2026 net loss $23.1M; unit sales of LYTENAVA double in Europe

## Summary
- Net loss of $23.1M ($0.38/share) vs net income of $17.4M ($0.72/share) in prior-year quarter.
- Adjusted net loss $13.5M ($0.22/share) vs adjusted net loss $21.6M ($0.89/share) a year ago.
- Revenue negatively impacted by returns reserve for short-dated product from UK distributor; unit sales more than doubled QoQ.
- Cash and equivalents $8.7M as of Dec 31, 2025 (excluding $2.4M ATM proceeds post-quarter).
- Submitted Type A meeting request to FDA to discuss ONS-5010 CRL for wet AMD; additional EU launches planned.

## SEC filing metadata
- accession: 0001104659-26-015887
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/0001104659-26-015887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/tm266557d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-015887
- JSON: https://secwatch.observer/filing/0001104659-26-015887.json
- Plain text: https://secwatch.observer/filing/0001104659-26-015887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.